These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 39262368

  • 21. An update on peptide-based therapies for type 2 diabetes and obesity.
    Bailey CJ, Flatt PR, Conlon JM.
    Peptides; 2023 Mar; 161():170939. PubMed ID: 36608818
    [Abstract] [Full Text] [Related]

  • 22. How May GIP Enhance the Therapeutic Efficacy of GLP-1?
    Samms RJ, Coghlan MP, Sloop KW.
    Trends Endocrinol Metab; 2020 Jun; 31(6):410-421. PubMed ID: 32396843
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes.
    Capozzi ME, DiMarchi RD, Tschöp MH, Finan B, Campbell JE.
    Endocr Rev; 2018 Oct 01; 39(5):719-738. PubMed ID: 29905825
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
    Goldenberg RM, Teoh H, Verma S.
    Curr Opin Cardiol; 2023 Nov 01; 38(6):539-545. PubMed ID: 37792556
    [Abstract] [Full Text] [Related]

  • 30. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review.
    Mathiesen DS, Bagger JI, Bergmann NC, Lund A, Christensen MB, Vilsbøll T, Knop FK.
    Int J Mol Sci; 2019 Aug 22; 20(17):. PubMed ID: 31443356
    [Abstract] [Full Text] [Related]

  • 31. Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future.
    Caruso I, Giorgino F.
    Endocrine; 2024 Jun 22; 84(3):822-835. PubMed ID: 38472620
    [Abstract] [Full Text] [Related]

  • 32. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
    Malavazos AE, Iacobellis G, Dozio E, Basilico S, Di Vincenzo A, Dubini C, Menicanti L, Vianello E, Meregalli C, Ruocco C, Ragni M, Secchi F, Spagnolo P, Castelvecchio S, Morricone L, Buscemi S, Giordano A, Goldberger JJ, Carruba M, Cinti S, Corsi Romanelli MM, Nisoli E.
    Eur J Prev Cardiol; 2023 Jun 01; 30(8):680-693. PubMed ID: 36799940
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Incretin therapy for diabetes mellitus type 2.
    Holst JJ.
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb 01; 27(1):2-10. PubMed ID: 31815785
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
    Baggio LL, Drucker DJ.
    Mol Metab; 2021 Apr 01; 46():101090. PubMed ID: 32987188
    [Abstract] [Full Text] [Related]

  • 39. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q, Akindehin SE, Orsso CE, Waldner RC, DiMarchi RD, Müller TD, Haqq AM.
    Front Endocrinol (Lausanne); 2022 Apr 01; 13():838410. PubMed ID: 35299971
    [Abstract] [Full Text] [Related]

  • 40. Newer pharmacological interventions directed at gut hormones for obesity.
    Camilleri M, Acosta A.
    Br J Pharmacol; 2024 Apr 01; 181(8):1153-1164. PubMed ID: 37917871
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.